angioedema

LSP-249是血浆 kallikrein 的抑制剂，用于血管性水肿的研究，EC50值小于 100 nM。

Avoralstat (BCX4161) 是血浆激肽释放酶(PKK)抑制剂，具有口服活性，可用于遗传性血管性水肿的研究。

Fexofenadine hydrochloride (Terfenidine carboxylate hydrochloride) 是一种抗组胺药，用于治疗过敏性鼻炎、血管性水肿和慢性荨麻疹。

Berotralstat (BCX7353) is a second-generation, synthetic, and orally active plasma kallikrein inhibitor with low toxicity. It is highly specific and effectively used in the research of hereditary angioedema (HAE) attacks. Berotralstat functions by inhibiting the enzymatic activity of plasma kallikrein, which is responsible for the release of bradykinin. This blocking mechanism targets the major biologic peptide involved in the promotion of swelling and pain associated with HAE attacks[1][2].

Plasma kallikrein-IN-3, a potent inhibitor ( IC 50 : 0.15 μM) of plasma kallikrein, finds application in research related to hereditary angioedema, diabetic macular edema, and diabetic retinopathy [1].

Icatibant acetate 是一种特异性缓激肽 B2 受体拮抗剂，其 IC50=1.07 nM，Ki=0.798 nM。

KKI-5 acetate(97145-43-2 free base) 是一种丝氨酸蛋白酶抑制剂，可抑制激肽释放酶和纤溶酶。 KKI 5 可能表现出抗癌化疗益处，也可用作血管性水肿的治疗方法。

Ecallantide (DX-88) 是高特异性重组血浆激肽释放酶抑制剂，用于阻断缓激肽生成，治疗血管性水肿急性发作。

KKI 5 is a serine protease inhibitor that inhibits kallikrein and plasmin. KKI 5 may exhibit anticancer chemotherapeutic benefit and may also be used as a treatment for angioedema.

Lanadelumab (SHP643) 是一种针对血浆激肽释放酶 (plasma kallikrein (pKal)) 的人源化IgG1单克隆抗体，Ki 值为 0.12 nM。Lanadelumab 抑制游离和 HMWK 结合的 pKal。Lanadelumab 具有研究遗传性血管性水肿的潜力

Carbinoxamine, an anticholinergic and antihistamine agent, is used for hay fever, angioedema, vasomotor rhinitis, mild urticaria, dermatographism and allergic conjunctivitis. It is a histamine antagonist, specifically an H1-antagonist.

Ecallantide (DX-88) TFA 是一种特异性的重组血浆激肽释放酶(Kallikrein)抑制剂，作用于缓激肽的生成过程以减少其产生。此化合物主要用于预防和治疗血管性水肿的急性攻击。

Plasma kallikrein-IN-2 是一个有效的 plasma kallikrein (PKal)抑制剂，IC50值为 0.1 nM。Plasma kallikrein-IN-2 可用于遗传性血管水肿、糖尿病性黄斑水肿、糖尿病视网膜病变的研究。

Garadacimab (CSL312) 是有效的全人 IgG4 单克隆抗体，针对活化因子 XII (FXIIa)。Garadacimab 可用于研究遗传性血管性水肿。 。